JP2008527034A - アンジオテンシンｉ誘導体 - Google Patents

アンジオテンシンｉ誘導体 Download PDF

Info

Publication number
JP2008527034A
JP2008527034A JP2007552095A JP2007552095A JP2008527034A JP 2008527034 A JP2008527034 A JP 2008527034A JP 2007552095 A JP2007552095 A JP 2007552095A JP 2007552095 A JP2007552095 A JP 2007552095A JP 2008527034 A JP2008527034 A JP 2008527034A
Authority
JP
Japan
Prior art keywords
angiotensin
derivative
composition
day
neointima formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007552095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008527034A5 (enExample
Inventor
シム，メン・クウォン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University of Singapore
Original Assignee
National University of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University of Singapore filed Critical National University of Singapore
Publication of JP2008527034A publication Critical patent/JP2008527034A/ja
Publication of JP2008527034A5 publication Critical patent/JP2008527034A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2007552095A 2005-01-18 2006-01-17 アンジオテンシンｉ誘導体 Pending JP2008527034A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64516705P 2005-01-18 2005-01-18
PCT/SG2006/000006 WO2006078223A1 (en) 2005-01-18 2006-01-17 Angiotensin i derivatives

Publications (2)

Publication Number Publication Date
JP2008527034A true JP2008527034A (ja) 2008-07-24
JP2008527034A5 JP2008527034A5 (enExample) 2009-03-26

Family

ID=36692528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007552095A Pending JP2008527034A (ja) 2005-01-18 2006-01-17 アンジオテンシンｉ誘導体

Country Status (4)

Country Link
US (1) US20080131406A1 (enExample)
EP (1) EP1846017A1 (enExample)
JP (1) JP2008527034A (enExample)
WO (1) WO2006078223A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008003736A1 (es) 2008-12-15 2009-05-29 Univ Pontificia Catolica Chile Uso de angiotensina (1-9) para preparar un medicamento, util para prevenir, revertir y/o disminuir el remodelado cardiovascular, pulmonar, renal y/o cerebral.
US8980250B2 (en) 2010-06-14 2015-03-17 Meng Kwoon Sim Use of des-aspartate-angiotensin I in inflammation-related pathologies and diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11199506A (ja) * 1997-10-24 1999-07-27 Natl Univ Of Singapore 新生内膜形成、再狭窄、および動脈硬化の予防および処置のための薬剤としてのデスアスパラギン酸アンジオテンシンｉの使用方法、予防および処置方法、および薬学的組成物
WO2001055176A2 (en) * 2000-01-27 2001-08-02 University Of Southern California Methods for inhibiting smooth muscle cell proliferation
WO2003002158A1 (en) * 2001-06-29 2003-01-09 National University Of Singapore The use of angiotensin i derivative as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854388A (en) * 1993-06-24 1998-12-29 Washington State University Research Foundation Angiotensin IV peptides and receptor
SG68529A1 (en) * 1995-05-25 1999-11-16 Univ Singapore The use of des-aspartate-angiotensin i (agr-val-tyr-ile-his-pro-phe-his-leu) as an anti-cardiac hypertrophic agent
WO2001049325A2 (en) * 2000-01-07 2001-07-12 Stichting Klinische Farmacologie Groningen Gene therapy to promote angiogenesis and/or the treatment of heart failure
US20050142130A1 (en) * 2001-01-04 2005-06-30 Roks Antonius J.M. Use of angiotensin-(1-7) for preventing and/or reducing the formation of neointima

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11199506A (ja) * 1997-10-24 1999-07-27 Natl Univ Of Singapore 新生内膜形成、再狭窄、および動脈硬化の予防および処置のための薬剤としてのデスアスパラギン酸アンジオテンシンｉの使用方法、予防および処置方法、および薬学的組成物
WO2001055176A2 (en) * 2000-01-27 2001-08-02 University Of Southern California Methods for inhibiting smooth muscle cell proliferation
WO2003002158A1 (en) * 2001-06-29 2003-01-09 National University Of Singapore The use of angiotensin i derivative as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders

Also Published As

Publication number Publication date
WO2006078223A1 (en) 2006-07-27
US20080131406A1 (en) 2008-06-05
EP1846017A1 (en) 2007-10-24

Similar Documents

Publication Publication Date Title
JP7378833B2 (ja) ヌトリン３ａおよびペプチドを用いた肺線維症の阻害
US8158589B2 (en) Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
US9938320B2 (en) Peptides for promoting angiogenesis and use thereof
US20090022729A1 (en) Methods and compositions for treating cardiac dysfunctions
JP2007326873A (ja) 肺動脈血管の血管平滑筋細胞の増殖を抑制する医薬を製造するための化合物の使用
JP2011241214A (ja) 線維症の処置におけるＣ５ａ受容体アンタゴニストの使用
US20210145922A1 (en) Ang (1-7) derviative oligopeptides for the treatment of pain
JP2005501823A (ja) 梗塞関連の心傷害および障害の治療および予防のための薬剤としてのアンジオテンシンｉ誘導体の使用
KR20160016872A (ko) 마르팡 증후군 및 관련 장애의 치료에서의 안지오텐신 펩티드
Ladenheim et al. Caudal hindbrain neuromedin B-preferring receptors participate in the control of food intake
US9249185B2 (en) Peptides for promoting angiogenesis and an use thereof
JP6897971B2 (ja) 関節炎を処置するための、方法および組成物
JP2008527034A (ja) アンジオテンシンｉ誘導体
CA2343352A1 (en) A method of treatment and agents useful for same
JP6254692B2 (ja) 認知機能不全を治療するための方法
JP4911854B2 (ja) 腎臓関連の疾患の治療薬および／または予防薬、並びにデス−アスパラギン酸塩−アンジオテンシンｉの使用方法
CN105828831A (zh) 新型肽组合物
EP3565575B1 (en) Ang (1-7) derivative oligopeptides for the treatment of pain
EP4032901A1 (en) Recombinant human neuregulin derivatives and use thereof
JP5742029B2 (ja) コレステロ−ル搬出ペプチド
HK40081680A (en) Recombinant human neuregulin derivatives and use thereof
WO2002072131A1 (fr) Médicaments contre des affections hépatiques
JP2007051086A (ja) コラーゲンまたはエラスチン代謝異常疾患の予防剤および治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110816

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120306